PSA Monitoring on TRT: When to Test & When to Worry

You start TRT, feel great, and then your next labs come back with a PSA that ticked up from 0.9 to 1.3 ng/mL. Your provider mentions it in passing, or worse, panics and tells you to stop testosterone entirely. Suddenly the therapy that fixed your energy and libido feels like it might be growing a prostate cancer.

This is one of the most misunderstood areas of TRT monitoring. The fear is decades old, rooted in a 1941 study that has since been thoroughly debunked. But the practical questions remain real: how much PSA rise is normal, how often should you test, and what number actually means it's time to see a urologist? This guide gives you the thresholds.

Key Takeaways

• TRT causes a small, one-time PSA rise of roughly 0.3 ng/mL in the first 3-6 months, then PSA stabilizes
• Testosterone does not cause prostate cancer -- the 80-year-old fear is based on a single discredited 1941 case
• The number that matters most is PSA velocity: a confirmed rise above 1.4 ng/mL in any 12-month period warrants urology referral
• Check PSA at baseline, 3-6 months, 12 months, then annually for men over 40
• Low testosterone artificially suppresses PSA, so starting TRT often reveals a truer baseline rather than creating new disease

Why TRT Affects PSA At All

Prostate-specific antigen (PSA) is a protein produced by prostate epithelial cells. Its production is partly androgen-dependent: the prostate needs a certain amount of testosterone (and its more potent metabolite DHT) to function normally and to make PSA.

When a man is hypogonadal, his prostate is under-stimulated. PSA output drops below where it would be in an androgen-replete state. This is the crucial and counterintuitive part: low testosterone artificially deflates PSA. A hypogonadal man with a PSA of 0.8 ng/mL might actually have a "true" androgen-replete PSA of 1.1 ng/mL hiding underneath the suppression.

When you start TRT and restore testosterone to a normal range, the prostate epithelium re-equilibrates. PSA production climbs back to where it would have been all along. This produces the small early rise that scares so many men and providers.

The Saturation Model

The reason this rise is small and self-limiting comes from the androgen saturation model, developed largely by Dr. Abraham Morgentaler. The prostate's androgen receptors become fully saturated at relatively low testosterone concentrations -- around 250 ng/dL of serum testosterone.

Below saturation, adding testosterone meaningfully increases prostate activity and PSA. Above saturation, the receptors are already maxed out, so adding more testosterone produces little to no additional prostate stimulation. This is why a man going from a hypogonadal 220 ng/dL up to 900 ng/dL sees a modest PSA bump, not a linear explosion. The receptors saturate early in that range and stop responding.

This model explains why decades of studies have failed to show that TRT pushes PSA into a continuous climb or causes prostate cancer. Once you're androgen-replete, more testosterone simply does not equal more prostate growth.

The 80-Year Myth That Still Drives Bad Advice

The fear that testosterone fuels prostate cancer traces to a 1941 paper by Charles Huggins, who reported that one patient's metastatic prostate cancer worsened when given testosterone. That single observation, in one man whose PSA could not even be measured (PSA testing did not exist until the 1980s), became dogma for two generations of physicians.

Modern evidence has dismantled it. Pooled analyses of thousands of men on TRT show no increased incidence of prostate cancer compared to untreated men. The landmark TRAVERSE trial, published in 2023, followed over 5,000 hypogonadal men with cardiovascular risk and found no significant increase in prostate cancer or aggressive prostate cancer in the testosterone group versus placebo. We cover this history in depth in our guide on TRT and prostate cancer myths.

None of this means PSA monitoring is optional. It means the monitoring exists to catch the rare coincidental cancer -- a cancer that was already there -- not because testosterone causes one. TRT can unmask an existing undetected cancer by restoring the PSA that low testosterone had been suppressing. That is a meaningful safety reason to monitor, and it is different from saying testosterone is carcinogenic.

What a Normal PSA Rise Looks Like

Here is what the data shows for a typical man starting TRT:

• Baseline: Your pre-TRT PSA, ideally drawn before the first injection
• Months 3-6: A rise of roughly 0.3 ng/mL on average. Some men see slightly more, some none at all
• Month 12 and beyond: PSA stabilizes at the new, androgen-replete level and tracks with normal age-related changes (a slow drift upward over years)

A jump from 0.9 to 1.2 ng/mL in the first six months is textbook normal. A jump from 1.0 to 2.5 ng/mL in three months is not, and needs evaluation.

PSA Ranges and What They Mean on TRT

PSA (ng/mL)	Assessment	Action
Below 1.0	Low, reassuring	Routine annual monitoring
1.0-2.5	Normal for most men	Routine monitoring; track velocity
2.5-4.0	Upper normal / gray zone	Confirm with repeat test; consider free PSA, urology input if rising
Above 4.0	Elevated	Urology referral before continuing or starting TRT
Above 4.0 with rapid rise	Concerning	Prompt urology evaluation, likely further workup

These thresholds are age-adjusted in practice -- a PSA of 3.0 means something different in a 45-year-old than in a 70-year-old. But the absolute 4.0 ng/mL line remains the most widely used referral trigger.

The Number That Actually Matters: PSA Velocity

The single absolute PSA value is less informative than how fast it is changing over time. This is PSA velocity.

The most actionable threshold: a confirmed rise greater than 1.4 ng/mL within any 12-month period warrants urology referral. This figure comes from the Endocrine Society's clinical practice guideline and is the cleanest decision rule most providers use on TRT.

Why velocity beats a single number:

• A man whose PSA goes 1.0 → 1.2 → 1.3 over three years is following an expected, benign drift
• A man whose PSA goes 1.0 → 2.6 in twelve months has a velocity of 1.6 ng/mL/year -- over the threshold -- and needs workup, even though 2.6 is technically "normal range"

One caveat: a single elevated reading is never enough to act on. PSA fluctuates with ejaculation (abstain 48 hours before the draw), recent cycling or prostate exams, urinary tract infections, and even vigorous exercise. Always confirm a concerning result with a repeat test 4-6 weeks later before making decisions. Many "alarming" PSA spikes vanish on the confirmatory draw.

The Monitoring Schedule

PSA is part of the standard TRT safety panel alongside hematocrit, estradiol, and a metabolic panel. Here is the schedule most TRT-literate providers follow for men over 40. (Men under 40 with no risk factors may test less frequently, since prostate cancer is rare in that group, but baseline and annual checks are still prudent.)

Timepoint	What to Check	Why
Baseline (pre-TRT)	PSA + digital rectal exam if indicated	Establish true starting point; rule out existing elevation
3-6 months	PSA	Capture the expected early rise; flag anything excessive
12 months	PSA	Confirm stabilization; calculate first-year velocity
Annually thereafter	PSA	Long-term surveillance and velocity tracking
After any concerning result	Repeat PSA in 4-6 weeks	Confirm before acting; rule out transient causes

Before starting TRT, a baseline PSA above 4.0 ng/mL (or above 3.0 ng/mL in higher-risk men -- Black men and those with a first-degree relative who had prostate cancer) should prompt a urology evaluation first. This is not because testosterone is dangerous, but because you want to clear the prostate before introducing a variable that will nudge PSA upward.

For the full picture of what else belongs on your panel and how often, see our TRT bloodwork schedule and our guide on how to read testosterone labs.

How PSA Connects to the Rest of Your TRT Monitoring

PSA does not exist in isolation. A few practical links:

Age and dose. Older men starting TRT have a higher baseline prostate cancer prevalence simply by age, so PSA monitoring carries more weight after 50. If you are in this group, our TRT after 50 protocol guide covers the monitoring adjustments that matter.

Hematocrit. The other primary safety lab on TRT is hematocrit, which rises predictably and needs its own management plan. PSA and hematocrit are the two numbers that most often prompt providers to adjust or pause therapy -- learn the real thresholds in our high hematocrit guide.

DHT. Because DHT is the more potent prostate androgen, men on protocols that elevate DHT may theoretically see slightly more prostate activity. In practice this rarely changes PSA management, but it is worth understanding -- see DHT on TRT and when to test it.

The thread connecting all of these is that good TRT is monitored TRT. A provider who orders a baseline PSA, repeats it on schedule, and knows the velocity threshold is doing it right. A provider who either ignores PSA entirely or reflexively stops testosterone over a 0.3 ng/mL rise is not.

What to Do If Your PSA Rises

If your PSA crosses a threshold, do not panic and do not abruptly self-discontinue TRT. The sequence:

1. Repeat the test in 4-6 weeks, abstaining from ejaculation for 48 hours and avoiding cycling or a recent prostate exam before the draw. Many flagged results normalize.
2. Calculate velocity. Is the confirmed change above 1.4 ng/mL over 12 months? Is the absolute value above 4.0?
3. Get a free PSA percentage if you are in the 2.5-4.0 gray zone. A higher free-PSA fraction points toward benign causes; a low fraction raises suspicion.
4. Refer to urology if velocity or absolute value crosses the line. The urologist decides on further workup such as an MRI or biopsy. This is a coincidental finding to evaluate, not a verdict on your TRT.

Whether you continue TRT during a urology workup is a shared decision with your providers. In many cases therapy continues; in some it pauses pending results.

The Bottom Line

PSA monitoring on TRT is straightforward once you separate the real signal from the 80-year-old myth. Expect a small one-time rise of around 0.3 ng/mL in the first few months as your prostate re-equilibrates to a normal androgen environment, then stabilization. Testosterone does not cause prostate cancer, but monitoring exists to catch a coincidental, pre-existing one that restored PSA might unmask.

Track velocity, not just the single number. A confirmed rise above 1.4 ng/mL in twelve months, or an absolute PSA above 4.0, is your referral trigger. Everything below that, on a stable trajectory, is the expected behavior of a healthy prostate on properly dosed testosterone.

The most important variable is the provider running your labs. If you want a clinic that monitors PSA on a real schedule and understands the saturation model rather than panicking at the first uptick, compare your options in our independent clinic reviews.

References

1. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364

2. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107-117. PMID: 37326322

3. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310-320. PMID: 18838208

4. Khera M, et al. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy. BJU Int. 2011;107(8):1216-1222. PMID: 21392244

5. Cui Y, et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132-143. PMID: 24445948

6. Huggins C, Hodges CV. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293-297.